Molecular and Translational Anti-Inflammatory Strategies After Abdominal and Liver Surgery: From Immunonutrition to Cell-Based Therapies
- 1Department of Medical Biophysics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland
Abstract
Postoperative inflammation influences recovery after abdominal and liver surgery. This narrative review critically synthesizes clinical and translational evidence on inflammation-modulating strategies using a structured search of PubMed, Scopus, Web of Science, and Cochrane Library for publications from 2015 to 2025. Case reports, pediatric studies, and publications lacking clinical or translational relevance were excluded. Immunonutrition and early enteral nutrition are the most established approaches, with benefits for postoperative recovery and infectious complications. Perioperative corticosteroids in liver resection and short-course antibiotics following adequate source control offer procedure- and indication-specific benefits. Emerging interventions, including microbiota modulation, N-acetylcysteine, activation of nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling, and cell-based therapies, show biological promise but lack sufficient high-quality clinical evidence for routine implementation. Established strategies should be integrated into Enhanced Recovery After Surgery pathways according to patient risk and surgical context. Personalized management requires prospective validation of emerging therapies and candidate biomarkers, including interleukin-6, C-reactive protein, and heme oxygenase-1, with standardized assays and sampling schedules.
Related
- HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges
- Modulating the NLRP3/IL-1β Axis in Age-Related Atherosclerosis: Natural Products, Molecular Mechanisms, and Translational Perspectives—A Narrative Review
- Terpenoids: A Comprehensive Review on Biosynthesis, Applications and Enhancement Strategies for Translational Research
- New Advances in Bioactive Compounds in Health and Disease: From Molecular Mechanisms to Translational Perspectives
- AAV9 Gene Therapy for Ovarian Dysfunction and Reproductive Aging: Molecular Mechanisms, Therapeutic Targets, and Translational Perspectives
BibTeX
@article{pietrzyk2026molecular,
title = {{Molecular and Translational Anti-Inflammatory Strategies After Abdominal and Liver Surgery: From Immunonutrition to Cell-Based Therapies}},
author = {Barbara Pietrzyk and Wiktor Pierzchała and Jedrzej Mikolajczyk and Piotr Lis and Anna Heliasz and Bruno Kaczmarczyk},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219727},
url = {https://www.mdpi.com/1422-0067/27/21/9727},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Molecular and Translational Anti-Inflammatory Strategies After Abdominal and Liver Surgery: From Immunonutrition to Cell-Based Therapies
AU - Barbara Pietrzyk
AU - Wiktor Pierzchała
AU - Jedrzej Mikolajczyk
AU - Piotr Lis
AU - Anna Heliasz
AU - Bruno Kaczmarczyk
PY - 2026
DA - 2026/10/29
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219727
UR - https://www.mdpi.com/1422-0067/27/21/9727
AB - Postoperative inflammation influences recovery after abdominal and liver surgery. This narrative review critically synthesizes clinical and translational evidence on inflammation-modulating strategies using a structured search of PubMed, Scopus, Web of Science, and Cochrane Library for publications from 2015 to 2025. Case reports, pediatric studies, and publications lacking clinical or translational relevance were excluded. Immunonutrition and early enteral nutrition are the most established approaches, with benefits for postoperative recovery and infectious complications. Perioperative corticosteroids in liver resection and short-course antibiotics following adequate source control offer procedure- and indication-specific benefits. Emerging interventions, including microbiota modulation, N-acetylcysteine, activation of nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling, and cell-based therapies, show biological promise but lack sufficient high-quality clinical evidence for routine implementation. Established strategies should be integrated into Enhanced Recovery After Surgery pathways according to patient risk and surgical context. Personalized management requires prospective validation of emerging therapies and candidate biomarkers, including interleukin-6, C-reactive protein, and heme oxygenase-1, with standardized assays and sampling schedules.
SN - 1422-0067
ER -